MDL-1 Ligand Modulation for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive regimes for controlling unwanted immune responses in diseases like inflammation, autoimmune diseases, and transplant rejection are limited by side effects and toxicity, and there is a need to regulate the interaction between MDL-1 and its binding partner Galectin-9 to manage chronic inflammation and improper microbial clearance.
Innovation Solution
Development of a method involving a compound that binds to MDL-1, preventing its interaction with Galectin-9, using antibodies or soluble receptor-Ig fusion proteins to modulate the interaction between MDL-1 and Galectin-9, thereby controlling the activation of myeloid lineage cells and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressive regimes (corticosteroid, cyclosporin, rapamycin) are used to control unwanted immune responses, then T cell proliferation is inhibited, but side effects and toxicity increase
Solution Approach 1:
The patent introduces monoclonal antibodies as intermediary agents that specifically target cell surface proteins involved in T cell activation pathways (CD3, CD4, CD8, CD25, B7-1, B7-2, CD152, CTLA4). These antibodies mediate immune suppression by blocking specific molecular interactions rather than broadly inhibiting T cell function, thereby achieving immunosuppression with reduced side effects and toxicity compared to traditional regimens.
2Reliability
If MDL-1 interacts with Galectin-9 to activate myeloid lineage cells, then immune response is enhanced, but chronic inflammation and improper microbial clearance occur
Solution Approach 1:
The patent extracts or separates the harmful interaction between MDL-1 and Galectin-9 by introducing compounds that specifically bind to Galectin-9, preventing its interaction with MDL-1. This extraction of the pathogenic signaling pathway allows the immune system to maintain beneficial functions while eliminating the specific interaction that leads to chronic inflammation and improper microbial clearance.
3Reliability
If T cell depleting agents (monoclonal antibodies against CD3, CD4, CD8) are used to reduce rejection, then graft survival is prolonged, but immune response is overly suppressed
Solution Approach 1:
The patent applies local quality by using monoclonal antibodies that target specific cell surface proteins on T cells and myeloid cells, thereby exerting immunosuppressive effects locally at the molecular interaction level rather than globally depleting entire T cell populations. This localized approach allows for more precise control of immune responses while maintaining graft survival.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits the phosphorylation of DAP12 and reduces inflammation, offering a potential treatment for inflammatory disorders by specifically targeting the MDL-1/Galectin-9 interaction, thereby minimizing side effects and improving immune response control.
Implementation Method 1
using antibodies or soluble receptor-Ig fusion proteins to modulate the interaction between MDL-1 and Galectin-9
Implementation Method 2
providing a compound that is capable of binding to the lectin-like molecule at a binding site of the lectin
Implementation Method 3
effectively inhibits the phosphorylation of DAP12 and reduces inflammation
Data Source
AI summary
The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.